SCHEMBL18409476

SCHEMBL18409476

O=C(c1ccccc1)N1CCN(Cc2nc(-c3cccc(F)c3)c(-c3cccc(F)c3)[nH]2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 3/20 0.48
MAPK1 P28482 2/20 0.48
KDM4E B2RXH2 5/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
SLC2A1 P11166 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 2/20 0.46
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4D Q08499 1/20 0.46
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18409478 0.95 ALDH1A1 (0.53) ALDH1A1GAACYP2D6MAPK1KDM4E
SCHEMBL18409479 0.94 ALDH1A1 (0.47) ALDH1A1GAAKDM4ESLC2A1L3MBTL1
SCHEMBL18409509 0.90 ABL1 (0.46) ALDH1A1GAACYP2D6MAPK1MEN1
SCHEMBL18409474 0.88 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2TSHRLMNA
SCHEMBL18409495 0.87 KDM4E (0.52) ALDH1A1MAPK1KDM4EMEN1KMT2A
SCHEMBL18409506 0.86 CYP3A4 (0.45) ALDH1A1CYP2D6MAPK1KDM4EMEN1
SCHEMBL18409662 0.84 DRD2 (0.47) ALDH1A1GAAKDM4EMEN1KMT2A
SCHEMBL18409305 0.82 DRD4 (0.51) ALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL18409622 0.81 DRD2 (0.51) ALDH1A1GAACYP2D6KDM4EMEN1
SCHEMBL18409498 0.79 SMO (0.49) ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844051-B2 Substituted oxazoles for the treatment of cancer THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY 2020-11-24 US disclosed
US-20200339554-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2020-10-29 US disclosed
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2018-07-26 US disclosed
WO-2017011920-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS VHL, TP53, CD44 ALDH1A1 325/4885GAA 208/4885CYP2D6 1544/4885
US-10844051-B2 Substituted oxazoles for the treatment of cancer OXA1L, PDCD1, MCL1 ALDH1A1 292/4885GAA 1574/4885CYP2D6 381/4885
US-20200339554-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS KRAS, NRAS, VHL ALDH1A1 2287/4885GAA 690/4885CYP2D6 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.